Pharming Group N.V. Return on Equity

Pharming Group N.V. (PHAR) currently reports a ROE of 3.13%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Pharming Group N.V.'s ROE history and peer comparisons.

Pharming Group N.V.'s ROE of 3.13% is lower than the Healthcare sector average of 11.15%. That is roughly 72.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Pharming Group N.V.'s current 3.13% should be judged against Healthcare norms (sector average: 11.15%) and against PHAR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 3.13%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Pharming Group N.V., and consider following PHAR for alerts when major investors trade the stock.

Pharming Group N.V. is classified in the Healthcare sector. On ROE, it currently shows 3.13% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHAR with unrelated industries.